PDCD1 and melanoma: However, this real-world single-center analysis is the first study to our knowledge that evaluates the longitudinal development of irAE in anti-PD-1 treated melanoma patients and their relationship to response and survival outcomes along with other demographic determinants of response and autoimmunity including age, gender and BMI.